💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based technology-driven contract development and manufacturing organization (CDMO), providing integrated solutions in custom synthesis, process research and development (R&D), and manufacturing.…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A weak, stagnant business, fully valued.
Suven Pharmaceuticals is scored on the pharma / healthcare framework. It keeps a slim 6.5% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 2.45× reported profit. Free cash flow is worth about 0.7% of its market value.
Over the last 3 years revenue compounded at 18%/yr and profit at -29%/yr. Book value itself has compounded 33%/yr — the hallmark of a genuine compounder. Return on equity is a weak 5.0%. In the latest quarter profit fell 644% versus the prior quarter.
At 92× earnings, the stock sits at the 76th percentile of its own 3.6-year range — the expensive end of where it has historically traded. Today's price already implies ~47%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 283.37 | — | — |
| P/B | 4.24 | 4.1 | worse |
| EV/EBITDA | 53.59 | 19.33 | worse |
| ROE | 5.05 | — | — |
| ROCE | 5.47 | 14.41 | worse |
| ROA | 1.02 | 1.64 | worse |
| Quick Ratio | 1.91 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue declined 14% in the latest year — a break from prior trajectory. 18% CAGR over 3 years — steady double-digit compounder. Growth is decelerating — latest year grew slower than the year before.
Revenue is outpacing profit (18% vs -29%) — costs are rising faster than the top line. The latest year saw a -69% swing — check if it's a one-off or structural.
Operating margin has compressed from 40% to 9% — costs or competition are eating into profitability. Interest or tax burden is shrinking — more of the operating profit is reaching the bottom line. Margins have declined for 3 consecutive years — watch for a structural cost problem.
ROE at 4% — modest; the capital isn't working hard. Capital efficiency declining — ROE down 20pp.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. Profit grew faster than EPS (-29% vs -34%) — share dilution is eroding per-share value. -34% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 2.5× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 30% QoQ — could be seasonality or a genuine slowdown.
1 of 4 quarters loss-making — quarterly profitability is uneven. Profit fell 644% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly margins are compressing (12% → -10%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 57.5% — majority control intact.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.